Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis
Journal of Drugs in Dermatology · 2025
DOI: 10.36849/jdd.9049 ↗At a glance
Übersichtsarbeit in Journal of Drugs in Dermatology, 2025. Written by Omar Alani and 7 co-authors. Major MEDLINE topics: Dermatitis, Atopic, Cardiovascular Diseases, Heterocyclic Compounds, 3-Ring, Venous Thromboembolism. Cited 3 times so far (Crossref).
Topics: Thromboseprophylaxe
Abstract (original language)
BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin condition associated with risk of cardiovascular disease (CVD), potentially mediated by persistent systemic inflammation. Upadacitinib (UPA), a selective Janus kinase 1 (JAK1) inhibitor, effectively reduces AD-related inflammation and may confer additional cardioprotective and thromboprotective benefits. OBJECTIVE: This review evaluates the incidence of major adverse cardiovascular events (MACE) in patients with AD, comparing background rates reported in the literature to long-term MACE rates observed in clinical trials of UPA. METHODS: A literature review was conducted across PubMed, SCOPUS, and EMBASE to identify studies reporting MACE and venous thromboembolism (VTE) rates in moderate-to-severe AD populations. Long-term (5-year) incidence rates in UPA-treated patients were extracted from clinical trials. Reported background incidence rates in AD populations were included. RESULTS: MACE rates in the background AD populations ranged from 0.3 to 1.2 per 100 patient-years (PY), whereas UPA-treated patients exhibited lower rates (15 mg: 0.2, 30 mg:
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
Alani, O., Wang, D., Wahood, S., Obagi, S., Dasilva, D., Zirwas, M. J., Galimberti, F., & Bunick, C. G. (2025). Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.9049
Vancouver
Alani O, Wang D, Wahood S, Obagi S, Dasilva D, Zirwas MJ, et al. Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis. Journal of Drugs in Dermatology. 2025. doi:10.36849/jdd.9049
BibTeX
@article{Alani2025,
author = {Alani, Omar and Wang, David and Wahood, Samer and Obagi, Sabine and Dasilva, Diego and Zirwas, Matthew J and Galimberti, Fabrizio and Bunick, Christopher G},
title = {Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis},
journal = {Journal of Drugs in Dermatology},
year = {2025},
doi = {10.36849/jdd.9049}
}
EUVIMED